Gabriela Morar-Bolba

CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial

Justin Stebbing, Y. Baranau, Valeriy Baryash et al. · The Lancet Oncology · 2017 · 123 citations · Full text

Medicine, Oncology, Breast Oncology +13

Aberrant miRNAs expressed in HER-2 negative breast cancers patient

Cornelia Braicu, Lajos Ráduly, Gabriela Morar-Bolba et al. · Journal of Experimental & Clinical Cancer Research · 2018 · 54 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

Solid Plasmonic Substrates for Breast Cancer Detection by Means of SERS Analysis of Blood Plasma

G. STIUFIUC, Valentin Toma, Mihail Buse et al. · Nanomaterials · 2020 · 34 citations · Full text

Natural Sciences, Bioengineering, Biomedical Engineering +17

Genetic alterations in sporadic triple negative breast cancer

Laura Pop, Roxana Cojocneanu, Valentina Pileczki et al. · The Breast · 2017 · 30 citations

Medicine, Genetics, Molecular Genetics +11

Double-blind, randomized phase III study to compare the efficacy and safety of CT-P6, trastuzumab biosimilar candidate versus trastuzumab as neoadjuvant treatment in HER2 positive early breast cancer (EBC).

Justin Stebbing, Y. Baranau, V. Baryash et al. · Journal of Clinical Oncology · 2017 · 13 citations

Medicine, Oncology, Pharmacology +17